Sanofi (SNY) · Company profile · Eqvero

Sanofi

SNYNasdaq

Unit: EUR	FY2025	FY2024	FY2023	FY2022	FY2021
Cost of revenue	13.05 bn EUR	13.21 bn EUR	12.63 bn EUR	11.88 bn EUR	12.26 bn EUR
Gross profit	33.67 bn EUR	31.08 bn EUR	28.99 bn EUR	28.68 bn EUR	26.92 bn EUR
Research and development expense	7.84 bn EUR	7.39 bn EUR	6.51 bn EUR	6.5 bn EUR	5.69 bn EUR
Selling, general and administrative expense	9.54 bn EUR	9.18 bn EUR	8.93 bn EUR	8.74 bn EUR	9.56 bn EUR
Operating profit	6.34 bn EUR	7.25 bn EUR	6.96 bn EUR	10.16 bn EUR	8.13 bn EUR
Interest expense	563 m EUR	1.07 bn EUR	1.29 bn EUR	430 m EUR	368 m EUR
Income tax expense	1.04 bn EUR	1.2 bn EUR	1.02 bn EUR	1.91 bn EUR	1.56 bn EUR
Net income (reported basis)	7.85 bn EUR	5.62 bn EUR	5.44 bn EUR	8.48 bn EUR	6.28 bn EUR
Net income attributable to owners of the parent	7.81 bn EUR	5.56 bn EUR	5.4 bn EUR	8.37 bn EUR	6.22 bn EUR
Basic earnings per share	6.4 EUR/share	4.44 EUR/share	4.31 EUR/share	6.69 EUR/share	—
Diluted earnings per share	6.37 EUR/share	4.43 EUR/share	4.3 EUR/share	6.66 EUR/share	—

Quotes are end-of-day data. Content is for research purposes and is not investment advice.